IRIS
GENTILE, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.953
NA - Nord America 3.246
SA - Sud America 2.264
EU - Europa 1.607
AF - Africa 239
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 14.315
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.248
US - Stati Uniti d'America 3.024
BR - Brasile 1.750
CN - Cina 1.520
VN - Vietnam 949
IT - Italia 673
KR - Corea 314
HK - Hong Kong 303
AR - Argentina 215
DE - Germania 182
FI - Finlandia 162
BD - Bangladesh 127
NL - Olanda 98
MX - Messico 94
GB - Regno Unito 92
IQ - Iraq 83
EC - Ecuador 81
RU - Federazione Russa 79
ZA - Sudafrica 72
IN - India 67
AT - Austria 65
CA - Canada 60
CO - Colombia 54
UA - Ucraina 50
FR - Francia 48
ID - Indonesia 46
PK - Pakistan 45
PY - Paraguay 39
MA - Marocco 38
VE - Venezuela 38
CL - Cile 35
UZ - Uzbekistan 28
EG - Egitto 26
PL - Polonia 23
JP - Giappone 22
UY - Uruguay 22
JO - Giordania 21
SE - Svezia 21
DZ - Algeria 20
TR - Turchia 20
AZ - Azerbaigian 18
KE - Kenya 17
PE - Perù 17
CZ - Repubblica Ceca 16
SN - Senegal 16
TN - Tunisia 16
KG - Kirghizistan 15
KZ - Kazakistan 15
DO - Repubblica Dominicana 14
NP - Nepal 14
BO - Bolivia 12
CR - Costa Rica 12
IL - Israele 12
AE - Emirati Arabi Uniti 11
ES - Italia 11
SA - Arabia Saudita 11
AL - Albania 10
BG - Bulgaria 9
GT - Guatemala 9
OM - Oman 9
PA - Panama 8
ET - Etiopia 7
HN - Honduras 7
LB - Libano 7
RO - Romania 7
BA - Bosnia-Erzegovina 6
JM - Giamaica 6
AO - Angola 5
PH - Filippine 5
PS - Palestinian Territory 5
QA - Qatar 5
SY - Repubblica araba siriana 5
BH - Bahrain 4
GA - Gabon 4
GR - Grecia 4
IE - Irlanda 4
LT - Lituania 4
MK - Macedonia 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
BY - Bielorussia 3
CH - Svizzera 3
DK - Danimarca 3
GE - Georgia 3
HU - Ungheria 3
KW - Kuwait 3
NG - Nigeria 3
NO - Norvegia 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
BE - Belgio 2
BN - Brunei Darussalam 2
BW - Botswana 2
CI - Costa d'Avorio 2
HR - Croazia 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
Totale 14.273
Salva come PNG Salva come JPEG
Città #
Singapore 1.145
Dallas 731
Boardman 648
Hefei 510
Ho Chi Minh City 389
Florence 315
Seoul 314
Hong Kong 301
Beijing 280
Ashburn 247
Shanghai 214
Hanoi 184
São Paulo 161
Helsinki 125
Munich 83
Los Angeles 79
Ogden 68
New York 61
Boydton 55
Rio de Janeiro 55
Santa Clara 53
Haiphong 48
Sesto Fiorentino 47
Amsterdam 46
Council Bluffs 46
Noto 45
Vienna 43
Brasília 41
Brooklyn 38
Guangzhou 36
Belo Horizonte 33
Dhaka 33
Biên Hòa 32
Da Nang 31
Quito 30
Johannesburg 28
The Dalles 27
Wuhan 27
Baghdad 26
Turku 24
Guayaquil 23
Tashkent 23
Mexico City 22
Amman 21
Rome 21
Tokyo 21
Chicago 20
Montreal 20
Porto Alegre 20
Washington 20
Atlanta 19
Chandler 19
Curitiba 19
Milan 19
Phoenix 19
San Francisco 19
Tianjin 19
Montevideo 18
Ninh Bình 18
Secaucus 18
Warsaw 18
Boston 17
Buenos Aires 17
Campinas 17
Fortaleza 17
Frankfurt am Main 17
Guarulhos 17
Recife 17
Asunción 16
Baku 16
Dakar 16
Hải Dương 16
Santo André 16
Seattle 16
Stockholm 16
Charlotte 15
Falkenstein 15
London 15
Thái Nguyên 15
Cape Town 14
Naaldwijk 14
Ribeirão Preto 14
Salvador 14
Caxias do Sul 13
Goiânia 13
Juiz de Fora 13
Rende 13
Can Tho 12
Lappeenranta 12
Nairobi 12
São Bernardo do Campo 12
Toronto 12
Bishkek 11
Cairo 11
Erbil 11
Maceió 11
Nuremberg 11
Sumaré 11
Chennai 10
Denver 10
Totale 7.660
Salva come PNG Salva come JPEG
Nome #
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study 141
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 140
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 138
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 126
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 100
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients 94
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 93
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 92
A novel phage display based platform for exosome diversity characterization 89
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 88
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 87
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 87
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 86
Momelotinib in myelofibrosis 84
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 82
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 78
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 78
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 77
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 77
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 76
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 75
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 75
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 73
Belantamab mafodotin in multiple myeloma 73
Elotuzumab in multiple myeloma 73
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 72
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 72
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 72
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 71
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 71
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? 71
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 71
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 70
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 70
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 70
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 70
Vaccination in Multiple Myeloma: Challenges and Strategies 70
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 70
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 69
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 69
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 68
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 68
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 68
Cerebral pheohyphomycosis due to curvularia species 67
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 67
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. 67
Selinexor in multiple myeloma 66
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 66
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay 66
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 65
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 65
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax 65
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 64
Acalabrutinib in chronic lymphocytic leukemia 64
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations 64
Iron chelation therapy 63
Ivosidenib in acute myeloid leukemia 62
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 62
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) 61
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 60
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 60
Teclistamab-cqyv in multiple myeloma 60
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 60
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. 60
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 60
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement 60
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant 60
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity 60
The use of ibrutinib before and after allogeneic stem cell transplantation 59
Myelodysplastic syndromes with ring sideroblasts 59
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 59
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 59
An old drug with a new future: bendamustine in multiple myeloma 59
High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications 59
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 57
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 56
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 56
Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple Myeloma 56
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 55
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. 55
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 55
An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. 55
Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 55
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 55
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 54
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 54
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 54
The role of corticosteroids in the current treatment paradigm for myelofibrosis 53
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary Immune Thrombocytopenia: a randomised trial 53
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 53
Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms 53
Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma 52
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort 52
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 52
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients 52
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy 51
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 51
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 51
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 50
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 50
Totale 6.862
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.063
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.063
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 1 0 1 0 0
2021/202224 0 2 0 0 2 0 0 6 1 1 5 7
2022/2023442 6 5 3 11 8 5 279 22 19 20 50 14
2023/20241.536 35 36 245 194 97 153 80 48 120 50 67 411
2024/20254.180 179 611 112 151 165 137 88 170 721 358 407 1.081
2025/20268.508 2.061 820 1.198 1.372 2.838 219 0 0 0 0 0 0
Totale 14.698